SCHEMBL3335173

SCHEMBL3335173

COCCOCOc1ccc(CCO)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
CASP1 P29466 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
SLCO1B3 Q9NPD5 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48
HRH3 Q9Y5N1 3/20 0.44
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
PPARA Q07869 1/20 0.41
NR3C1 P04150 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
CYP2D6 P10635 1/20 0.41
ADRA1A P35348 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616680 0.90 LMNA (0.59) LMNAMEN1USP2ALDH1A1CYP3A4
SCHEMBL10745619 0.86 CTNNB1 (0.43) LMNAMEN1USP2ALDH1A1CYP3A4
SCHEMBL7866230 0.85 CYP4F2 (0.47) LMNAMEN1USP2ALDH1A1CYP3A4
SCHEMBL1586551 0.81 LMNA (0.63) LMNAPPARAL3MBTL1
SCHEMBL6133622 0.81 HRH3 (0.53) LMNAMEN1USP2ALDH1A1CYP3A4
SCHEMBL14595233 0.80 APP (0.46) ALDH1A1SMN1; SMN2CTNNB1APPKDM4E
SCHEMBL6685948 0.80 ADRB2 (0.52) LMNAALDH1A1KMT2AADRB2ADRB1
SCHEMBL23266068 0.79 MEN1 (0.67) LMNAMEN1USP2ALDH1A1CYP3A4
SCHEMBL10748987 0.79 CTNNB1 (0.40) HRH3NR3C1ADRB2ADRB1CYP2D6
SCHEMBL3339746 0.79 KCNH2 (0.44) MEN1ALDH1A1CYP3A4KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404836-B2 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-03-26 US disclosed
US-20100144884-A1 NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US disclosed
EP-2164827-A2 NOVEL DERIVATIVES OF 3-PHENYL ACRYLIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development (FR) 2010-03-24 EP disclosed
WO-2008152334-A2 NOVEL DERIVATIVES OF 3-PHENYL ACRYLIC ACID ACTIVATING PPAR-TYPE RECEPTORS, METHOD FOR PREPARING SAME AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144884-A1 NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF PPARG, PPARA, PPARD LMNA 4312/4885MEN1 4630/4885USP2 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.